Skip to main content

Table 1 Comparision of clinical, demographic characteristics and laboratory findings between groups

From: Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction

 

NYHA I

(n = 28)

NYHA II

(n = 56)

NYHA III

(n = 36)

F/Xc

P

P1

P2

P3

Age (Year)

50.29 ± 5.08

52.73 ± 8.07

55.19 ± 5.40c

4.223

0.017a

0.119

0.005a

0.089

BMI

29.39 ± 3.75

29.91 ± 3.56

29.16 ± 2.99

0.577

0.563

0.513

0.786

0.305

HTN history (%)

9 (32.1%)

25 (44.6%)

20 (55.6%)

3.494

0.174

0.271

0.062

0.307

SBP (mmHg)

121.96 ± 11.49

124.73 ± 11.38

128.61 ± 11.63

2.747

0.098

0.300

0.051

0.116

DBP (mmHg)

82.14 ± 8.97

83.21 ± 7.89

85.42 ± 10.65

1.141

0.323

0.610

0.153

0.256

FBG (mg/dl)

89.32 ± 12.78

91.82 ± 11.61

94.83 ± 10.03

1.865

0.160

0.348

0.059

0.221

FI (uIU/ml)

9.90 ± 3.17

11.13 ± 4.21

12.24 ± 3.56

2.992

0.094

0.164

0.052

0.175

HOMA-IR

2.22 ± 0.88

2.51 ± 0.98

2.86 ± 0.95c

3.735

0.027a

0.179

0.008a

0.087

TC (mg/dl)

199.14 ± 48.30

210.23 ± 44.43

213.64 ± 38.81

0.930

0.397

0.276

0.191

0.716

LDL (mg/dl)

126.93 ± 40.11

129.56 ± 39.47

136.89 ± 34.26

0.628

0.536

0.766

0.302

0.370

HDL (mg/dl)

46.18 ± 7.15

44.71 ± 8.02

43.39 ± 7.49

1.045

0.355

0.411

0.151

0.420

TGs (mg/dl)

143.21 ± 34.38

148.73 ± 47.61

152.06 ± 29.47

0.388

0.679

0.552

0.382

0.698

Hemoglobin (g/dl)

11.70 ± 1.10

11.66 ± 1.00

11.53 ± 0.83

0.316

0.730

0.874

0.477

0.505

BNP (Pg/ml)

51.82 ± 9.54

58.34 ± 12.14b

70.36 ± 13.86c,d

19.870

0.001a

0.022a

0.001a

0.001a

Testosterone (ng/ml)

3.79 ± 1.54

2.96 ± 0.75b

2.49 ± 0.79c,d

13.408

0.001a

0.001a

0.001a

0.031a

Testosterone deficiency (%)

5 (17.9%)

9 (16.1%)

16 (44.4%)c,d

18.798

0.002a

0.001a

0.836

0.002a

LAEF (%)

51.21 ± 9.63

48.71 ± 8.48

44.28 ± 6.06c,d

6.169

0.003a

0.187

0.001a

0.012a

ICAM-1 (ng/ml)

372.25 ± 76.99

350.30 ± 75.91

429.75 ± 72.68c,d

12.382

0.001a

0.210

0.003a

0.001a

P- selectin (ng/ml)

250.32 ± 94.32

315.55 ± 71.80b

321.33 ± 95.45c

6.840

0.002a

0.001a

0.001a

0.750

NO (μM)

14.94 ± 1.15

13.94 ± 0.79b

13.75 ± 0.75c

16.544

0.001a

0.001a

0.001a

0.307

ACEIs/ARBs (%)

10 (35.7%)

22 (39.3%)

12 (33.3%)

0.349

0.840

0.751

0.842

0.564

CCB (%)

5 (17.9%)

12 (21.4%)

7 (19.4%)

0.159

0.924

0.701

0.872

0.819

BB (%)

4 (14.3%)

16 (28.6%)

12 (33.3%)

3.117

0.210

0.147

0.081

0.628

Diuretics (%)

4 (14.3%)

12 (21.4%)

16 (44.4%)c,d

8.779

0.012a

0.432

0.010a

0.019a

  1. a; Statistical Significant Difference between all groups
  2. b; (P1) Statistical Significant Difference in comparison to NYHA I & II
  3. c; (P2) Statistical Significant Difference in comparison to NYHA I & III
  4. d; (P3) Statistical Significant Difference in comparison to NYHA II & III
  5. BMI Body Mass Index, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure
  6. HOMA-IR Homeostatic Model Assessment of Insulin Resistance, FI Fasting Insulin
  7. FBG Fasting Blood Glucose, BNP Brain Natriuretic Peptide, LAEF Left atrium Ejection Fraction
  8. ARBs Angiotensin Receptor Blockers, CCB Calcium Channel Blockers, BB Beta Blocker
  9. NYHA New York Heart Association